Clinical and analytical progression and survival factors in T-cell cutaneous lymphoma (mycosis fungoides/Sézary syndrome);Factores clínicos y analíticos de progresión y supervivencia en linfomas cutáneos de células T (micosis fungoide/síndrome de Sézary)

Actas Dermo-Sifiliograficas

Volumn 94, Issue 6, 2003, Pages 356-367

  Gómez de la Fuente, Enrique ^a,c   Ortiz, Pablo ^a   Vanaclocha, Francisco ^a   Rodríguez Vázquez, María ^a   Piris, Miguel Ángel ^b   Algara, P ^b   Rodríguez Peralto, José Luis ^a   Iglesias, Luis ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Mortality; Mycosis fungoides; Prognosis; Risk factors; S zary syndrome; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; CARMUSTINE; CD7 ANTIGEN; CHLORMETHINE; CORTICOSTEROID; INTERFERON; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RETINOID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CHILD; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; EOSINOPHILIA; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; PATHOLOGICAL ANATOMY; PREDICTION; PROGNOSIS; PUVA; REMISSION; RISK FACTOR; SEZARY CELL; SEZARY SYNDROME; SKIN LYMPHOMA; STATISTICAL ANALYSIS; SURVIVAL; T CELL LYMPHOMA;

EID: 17544393925     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(03)76705-2     Document Type: Article

References (39)

1. Edelson RL. Cutaneous T-cell lymphoma: Mycosis fungoides, Sézary syndrome and other variants. J Am Acad Dermatol 1980;2:89-106.
2. Diamandidou E, Cohen PR, Kuzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996;88:2385-409.
3. Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol 1999;26:276-89.
4. Lamberg S, Green S, Byar D, et al. Status report of 376 mycosis fungoides patients at 4 years: Mycosis fungoides cooperative Group. Cancer Treat Rep 1979;63:701-7.
5. Weinstock M, Horn J. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer 1988;62:1658-61.
6. Sausville E, Eddy J, Makuch R, et al. Histopathological staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: Definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372-82.
7. Herman J, Roenigk H, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): Long term follow-up. J am Acad Dermatol 1995;33:234-42.
8. Quiros P, Kacinski B, Wilson L. Extent of skin involvement as a prognostic indicator of disease free survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996;77:1912-7.
9. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999;40:914-24.
10. Kim Y, Jensen R, Watanabe G, Varghese A, Hoppe R. Clinical stage IA (limited patch and plaque) mycosis fungoides. Arch Dermatol 1996;132:1309-13.
11. Toro J, Stoll H, Stomper P, Oscroff A. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997;37:58-67.
12. Kim Y, Chow S, Varghese A, Hoppe R. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999;135:26-32.
13. Zackheim H, Amin S, Kashani-Sabet M, McMillan A. Prognostic in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25.
14. Van Doorn R, Van Haselen CW, Van Voorst PC. Mycosis fungoides. Disease evolution and prognosis of 309 Dutch Patients. Arch Dermatol 2000;136:504-10.
15. Marti RM, Estrach T, Reverter JC, Mascaro JM. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991;127:1511-6.
16. Schmid MH, Bird P, Dummer R, Kempf W, Burg G. Tumor burden index is a prognostic tool for cutaneous T-cell lymphoma: A new concept. Arch Dermatol 1999;135:1204-8.
17. a ed. Philadelphia: Lippincott-Raven, 1997; p. 805-46.
18. Bunn PA Jr, Lamberg SI. Committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:725-8.
19. Burg G, Dummer R. Small plaque (digitate) parapsoriasis is an "abortive cutaneous T-cell lymphoma" and is not mycosis fungoides. Arch Dermatol 1995;131:336-8.
20. Ackerman AB, Schiff TA. If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an "abortive" one, it must be Mycosis fungoides. Arch Dermatol 1996;132:562-6.
21. Burg G, Dummer R, Nestle FO, et al. Cutaneous lymphoma consist of a spectrum of nosologically different entities including Mycosis fungoides and Small Plaque Parapsoriasis. Arch Dermatol 1996;132:567-72.
22. Muche M, Lukowsly A, Heim J, et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood but not in the skin of patients with small plaque parapsoriasis. Blood 1999;94:1409-17.
23. Haeffner AC, Smoller BR, Zepter K et al. Differentiation and clonality of lesional lymphocytes in small plaque parapsoriasis. Arch Dermatol 1995;131:321-4.
24. Simon M, Flaig MJ, Kind P, et al. Large plaque parapsoriasis: clinical and genotypic correlations. J Cutan Pathol 2000;27:57-60.
25. Weinstock MA, Horn JW. Mycosis fungoides in the United States-Increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.
26. Weinstock MA, Gardstein B. Twenty-Year trends in the reported incidence of mycosis fungoides associated mortality. Am J Pub Health 1999;89:1240-3.
27. Quaglino P, Zaccagna A, Verrone A, Dardano F, Bernengo MG. Mycosis fungoides in patients under 20 years of age: Report of 7 cases, review of the literature and study of the clinical course. Dermatology 1999;199:8-14.
28. Chuang TY, Su WPD, Muller SA. Incidence of cutaneous T-cell lymphoma and other rare skin cancer in a defined population. J Am Acad Dermatol 2003;23:254-6.
29. Jones GW, Kilson LD. The changing survival of patients with mycosis fungoides. A population-based assessment of trends in the United States. Cancer 1999;86:191-3.
30. Quiros P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous t-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 1997;38:1027-35.
31. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784.
32. Wasik MA, Vonderheid EC, Bigler RD, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Arch Dermatol 1996;132:42-7.
33. Ionescu MA, Tancrède-Bohin E, De la Salmoniere P, et al. Valeur pronostique de l'hyperéosinophilie sanguine au cous des lymphomes T cutanés primitifs. Ann Dermatol Venereol 2000;27:4538.
34. Dummer R, Heald PW, Nestle FO, et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (Interferon-γ receptor β-chain) Blood 1996;88:1383-9.
35. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996;107:833-837.
36. Schechtler GP, Sausville EA, Fischman AB, et al. Evaluation of circulating malignant cells provide prognostic information in cutaneous T-cell lymphoma. Blood 1987;69:841-49.
37. Fraser-Andrews EA, Woolford AJ, Russell-Jones R, Seed PT, Whittaker S. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000;114:117-21.
38. Delfau-Laure MH, Delac S, Lepage E, et al. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood 1998;92:3376-80.
39. Delfau-Larue MH, Petrella T, Lahet C, et al. Value of clonality studies of cutaneous T lymphocytes in the diagnosis and follow-up of patients with mycosis fungoides. J Pathol 1998;184:185-90.